Trends and Innovations in Pharmaceutical R&D Outsourcing

Antal K. Hajos
DOI: https://doi.org/10.1002/9783527693405.ch17
2016-01-15
Abstract:While the outsourcing industry has been established decades ago, the past years have seen fundamental changes in pharmaceutical R&D outsourcing. Price pressures, merger and acquisition activities, and the increasing need for flexibility of resources and know‐how depending on pipeline needs have changed from a tactical purchase of “off‐the‐shelf” services to various models of strategic partnerships. Such need for true value‐enhancing partnerships is driven by globalization, increasing regulatory requirements that require specialist systems and processes, as well as increasing diversity of organizations that require outsourcing. Large Pharma is looking for innovation not only from smaller organizations considered more innovative such as biotechs but also contract research organizations (CROs) of various sizes, while biotech and midsize sponsors require global presence, systems, regulatory, and specialist knowledge. Accordingly, the CRO industry has started to become more differentiated into global key players and specialist and niche providers. Dedicated alliances have been established as the new dogma of outsourcing practices, however, often with disappointing results. The industry is torn between disparate forces of stringent financial control driven by procurement and the need to truly share risks and benefits between the partners to allow for commitment, value creation, and finally innovation needed to make development–outsourcing alliances work. The current chapter will discuss current approaches and challenge the drivers behind this genesis from both the sponsor and CRO side.
What problem does this paper attempt to address?